Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed Consent as documented by signature.~2. Male or female subjects 12 to 45 years old at screening visit.~3. Patients with convincing history of IgE-mediated systemic allergic reaction after consumption of peanut, and specific IgE above 95% positive predictive value:~   a. Peanut ≥ 15kU/L or Ara h 2 ≥ 5U/L~4. Patients without a convincing history of IgE-mediated systemic allergic reaction (for example only oral symptoms) after consumption of peanuts but with clear evidence of sensitization (SPT \> 3 mm and/or positive specific IgE (\> 0.1kU/l) and a positive standardized food challenge to peanut between V0 and V1.~Exclusion Criteria:~1. Subjects with a history of severe anaphylaxis to the incriminated food with the following symptoms: hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or incontinence).~2. Subjects with a history of systemic reaction to peanutskin prick test with commercial extract.~3. Uncontrolled asthma (Forced expiratory volume at one second (FEV1) \<70% of predicted value), active eosinophilic oesophagitis or any condition deemed incompatible by the investigator.~4. Known or suspected systemic mastocytosis.~5. Subject currently under allergen immunotherapy.~6. Subject/parent with excessive anxiety unlikely to cope with study conditions as per investigator's opinion.~7. Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study.~8. Use of immunosuppression or immunomodulatory drug (including anti-IgE or anti-Tumor necrosis factor (TNF)) within 1 year prior to inclusion in study.~9. Relative counter-indication or inability to use epinephrine auto-injector.~10. Subjects receiving beta-blockers or angiotensin converting-enzyme (ACE) inhibitors.~11. Women who are pregnant or breast feeding.~12. Intention to become pregnant during the course of the study, or inadequate contraceptive measures for women of child-bearing age (contraceptive measures considered adequate are: intrauterine devices, hormonal contraceptives, such as contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release).~13. Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.).~14. Diseases with a contraindication for the use of adrenalin (e.g. hyperthyroidism, glaucoma).~15. Known or suspected non-compliance, drug or alcohol abuse.~16. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.~17. Patients who are employees of the sponsor, institution or 1st grade relatives or partners of the investigators

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Peanut allergenic extract (Type: EXPERIMENTAL): injected peanut extract.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues